ULTOMIRIS® is now available as 300 mg/3 mL and 1,100 mg/11 mL concentrates for solution for infusion. This calculator is intended for use when administering doses of ULTOMIRIS® 100 mg/mL only.* For dosing information regarding ULTOMIRIS® 10 mg/mL (300 mg/30 mL), please see the full Summary of Product Characteristics.1
Drag the button across the slider bar in order to select your patient's body weight (kg). The body weight variable will automatically snap to the nearest recognised figure in line with the ULTOMIRIS® weight-based dosing.
With ULTOMIRIS® 100 mg/mL, there is an optimal vial mix (3 mL and 11 mL) for each patient weight cohort, ensuring there is no product wastage.1
In the absence of compatibility studies, ULTOMIRIS® 300 mg/30 mL concrete for solution for infusion must not be mixed with ULTOMIRIS® 300 mg/3 mL or 1,100 mg/11 mL concentrates for solution for infusion.1
In the absence of compatibility studies, ULTOMIRIS® 300 mg/30 mL concrete for solution for infusion must not be mixed with ULTOMIRIS® 300 mg/3 mL or 1,100 mg/11 mL concentrates for solution for infusion.1
* ULTOMIRIS® must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with haematological or renal, neuromuscular or neuroinflammatory disorders.1
† SOLIRIS® (eculizumab) is indicated for the treatment of refractory generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.2
‡ ULTOMIRIS® should only be diluted using sodium chloride 9 mg/mL (0.9 %) solution for injection.1
Adverse Event Reporting
Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com
healthcare professional